A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively.
Immune cells play a bigger role in high blood pressure than previously thought, opening doors for new treatments
A review in Nature Reviews Nephrology presents the association between immune cells and the development of hypertension, suggesting potential new therapeutic targets to mitigate the
April 26, 2024